Macroalgae-Derived Bioactive Molecules with Special Therapeutic Reference to Brain Disorders and Injury
A special issue of Marine Drugs (ISSN 1660-3397).
Deadline for manuscript submissions: closed (31 May 2020) | Viewed by 178
Special Issue Information
Dear Colleagues,
Bioactive natural products are promising for the development of novel therapeutic agents. In the past, terrestrial sources have been given priority over marine sources, but recently the latter have been focused on equally because of their highly diverse bioactive molecules with unique chemical structure and bioactivity. Macroalgae, one of the largest marine inhabitants, are abundant in diverse molecules and are primarily synthesized to cope with various environmental stimuli. However, these bioactive compounds have been reported to possess numerous medicinal values, including neuroprotective, antioxidant, anti-inflammatory, and immunomodulatory properties. With the growing prevalence of oxidative stress- and inflammation-mediated brain disorders, including Alzheimer’s, Parkinson’s, and Huntington’s diseases, natural product researchers and drug designers have been focusing their attention on the discovery and development of novel therapeutic leads from macroalgae-derived compounds or their skeleton. Many of these compounds modulate various molecular targets of brain-specific biochemical and signaling pathways, suggesting their therapeutic significance in the management of neurodegenerative disorders. This Special Issue will cover the isolation and characterization of novel compounds from macroalgae, the bioactivity of already known molecules, the structure–activity relationship, and the mechanism of neuroprotection against various toxic insults representing in vitro and in vivo models of neurodegeneration and brain injury. Both original research and review papers are welcome.
Prof. Dr. II SOO Moon
Prof. Dr. Abdul Hannan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- marine algae
- bioactive natural products
- structure-activity relationships
- pharmacological mechanism of action
- neuroprotection
- neurodegenrative disorders and ischemic stroke
